ESPR Q4 2017 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

-$148M

Operating Income

-$39M

Net Income

-$38M

EPS (Diluted)

$-1.44

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$278M

Total Liabilities

$33M

Stockholders' Equity

$245M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$148M	$0	—
Operating Income	-$39M	-$29M	-32.1%
Net Income	-$38M	-$29M	-30.9%